Critical Outcome Technologies Inc. (COTI)
TSX VENTURE : COT

Critical Outcome Technologies Inc. (COTI)

October 28, 2009 09:14 ET

Critical Outcome Technologies Inc. Provides Important Update on COTI-2’s Novel Mechanism of Action

LONDON, ONTARIO--(Marketwire - Oct. 28, 2009) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) provided an important update today regarding the specific cellular target and mechanism of action (MOA) for the Company's lead oncology candidate, COTI-2. Previous research confirmed that COTI-2 is a non- traditional inhibitor of AKT that promotes cell death at very low concentrations in susceptible human cancer cells. New experimental data clearly shows that COTI-2 inhibits the activation of the protein AKT2 and to a lesser extent AKT1, but not AKT3.

Specifically, COTI-2 is likely to be highly effective in treating human cancers that express high levels of the protein AKT/AKT2 such as endometrial, ovarian, pancreatic, colon, brain, leukemia, breast, small cell lung (SCLC) and non-small cell lung cancer (NSCLC). Experimental evidence indicates that COTI-2 prevents the activation of AKT/AKT2, thereby preventing its cancer promoting activities.

"We have previously shown that COTI-2 effectively inhibits the activation of AKT, but until now we were unable to explain exactly how COTI-2 brought about its effects in susceptible cancer cells. We have now demonstrated through a series of key experiments that the Pleckstrin Homology (PH) domain of AKT/AKT2 is a selective cellular target for COTI-2" said Dr. Wayne Danter President and CSO of COTI.

A summary of the experiment results can be found at www.criticaloutcome.com/091028_COTI-2_MOA.pdf

The ability of COTI-2 to target AKT/AKT2 in susceptible cancer cells makes it a valuable commercial asset with a broad potential market for two important reasons:

  1. Abnormal expression or activation of AKT/AKT2 is commonly found in a range of 20-100% of tumors depending upon the type of human cancer including endometrial, ovarian, pancreatic, colon, brain, leukemia, breast SCLC and NSCLC.
  2. The abnormal expression or activation of AKT/AKT2 has been associated with the emergence of resistance to many standard chemotherapeutic agents in many human cancers therefore; COTI- 2 may be a valuable addition in a combination therapy with many standard agents.

COTI will present this new data to prospective partners including executives from several major pharmaceutical organizations at BIO Europe taking place November 2-4, 2009 in Vienna, Austria. "The identification of a specific cellular protein target for COTI-2 dramatically increases the number of potential indications for COTI-2 and therefore the number of people that may benefit from its use," said Mr. Michael Cloutier, Chief Executive Officer of COTI. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2." COTI will be represented at BIO Europe by Mr. Michael Cloutier, Dr. Wayne Danter, and Mr. Michael Barr, Director of Business Development and Marketing.

Notice to Readers

Information contained in this press release may contain certain statements which constitute "forward- looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. Specifically, the statement "is likely to be highly effective" is a forward-looking statement. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

About Critical Outcome Technologies Inc. (COTI)

COTI is formed around a unique computational platform technology called CHEMSAS®, which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. Currently, six targeted libraries of lead compounds are under active development; small cell lung cancer, multiple sclerosis, HIV integrase inhibitors, acute myelogenous leukemia, colorectal cancer and Alzheimer's disease.

For further information, please visit the website at www.criticaloutcome.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Critical Outcome Technologies Inc.
    Michael Barr
    Director of Business Development and Marketing
    519-858-5157
    www.criticaloutcome.com